VisionCare Ophthalmic Technologies Announces Appointment of Industry Veteran, Thierry Clidiere, to its Board of Directors

Saratoga, CA – March 10, 2016

VisionCare Ophthalmic Technologies, Inc. (“VisionCare”) ,the developer, manufacturer and marketer of the Implantable Miniature Telescope (“IMT” by Dr. Isaac Lipshitz), the only FDA-approved surgical device for End-stage Age-related Macular Degeneration (AMD), announced today the appointment of ophthalmic industry veteran, Thierry Clidiere, to its Board of Directors. Mr. Clidiere joins current board members, Wolfgang Tolle, VisionCare’s President and CEO, and Life Science Alternative Funding representatives, Rich Gumer, Steve DeNelsky and David Kho.

“I’m excited to have Thierry join our Board of Directors,” commented Wolfgang Tolle, VisionCare’s President and CEO. “Thierry is a capable leader with a proven ability to grow markets in unique environments. His vast network of contacts worldwide, specifically in Europe, will be an asset to our team as we seek to expand our commercial efforts and bring our one-of-a-kind technology to AMD patients globally, especially in light of our recent achievement to obtain our first reimbursement outside the U.S., in parts of the U.K.”

Mr. Clidiere brings more than forty years of executive experience in marketing, sales and acquisition management within the pharmaceutical and medical device industry. Launching his career at Pfizer, Inc., Mr. Clidiere held various roles in the areas of sales, marketing, operations and business development in several of their international offices. In 1983, he joined Alcon Laboratories, where he spent the next 28 years in executive management positions including General Manager & President of Alcon Spain, Area President of Alcon Latin America, Area President of Alcon Europe, Middle East & Africa and, until 2011, Vice President Strategic and Commercial Integration Alcon/Novartis.

“The CentraSight telescope prosthesis is truly a life-changing product that has already benefitted hundreds of patients. I am excited to be part of this team and look forward to assisting the company in its growth process so that hundreds of thousands more patients can benefit from this impressive technology,” stated Mr. Clidiere.

About VisionCare
VisionCare Ophthalmic Technologies, Inc., headquartered in Saratoga, CA, is a privately-held company. The company is focused on the development, manufacturing, and marketing of implantable ophthalmic devices and technologies that are intended to improve vision and quality of life for individuals with End-stage Age-related Macular Degeneration. VisionCare’s Implantable Miniature Telescope was invented by company founders Yossi Gross and Isaac Lipshitz. Information on VisionCare can be found at www.visioncareinc.net.

About Life Sciences Alternative Funding LLC (“LSAF”)
LSAF provides non-dilutive, debt capital exclusively to fund the growth of commercial-stage life sciences companies with a primary focus on medical device and diagnostics companies. LSAF’s highly flexible structures provide long-term capital solutions ranging from $10 to $40 million. LSAF is majority owned by affiliates of the Perella Weinberg Partners Asset Based Value Strategy.

Media Contact:
Richard Powers, Executive Vice President
VisionCare Ophthalmic Technologies, Inc.
mail@visioncareinc.net
(408) 872-9393

MM01-0276 Rev 0 03/16

Released March 10, 2016